This phase II trial is evaluating the safety and effectiveness of an immunotherapy treatment in patients with B-Cell Non-Hodgkin Lymphoma that has gotten worse or not responded to prior treatment.
This trial is treating patients with B-Cell Non-Hodgkin Lymphoma, including the following subtypes: burkitt lymphoma/leukemia (BL), diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), gray zone lymphoma (GZL) and follicular lymphoma (FL).
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Safety and Efficacy of Tisagenlecleucel in Pediatric Subjects With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma (NHL)
Eligible patients will be enrolled and are allowed to start lymphodepleting chemotherapy as recommended in protocol, after which they will receive a single intravenous infusion of tisagenlecleucel. The efficacy of tisagenlecleucel will be evaluated via Overall Response Rate (ORR) which includes complete response (CR) and partial response (PR) as determined by local assessment. Safety assessments will be conducted until study completion.
Recruiting Hospitals Read More